Highly efficient production of HIV-1 <sub>AD8</sub> gp120 in mammalian cells

Human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins (Envs) interact with the CD4 receptor and CCR5/CXCR4 coreceptor expressed on target cells to mediate viral entry. Infection is initiated when the HIV-1 gp120 subunit of Envs binds to host receptors. gp120 can also be expressed as a soluble protein and is routinely used for different biophysical and immunization studies. Here, we compared the transient and stable expression of monomeric HIV-1<sub>AD8</sub> gp120 in two closely related 293 cell lines grown in suspension. We used an HIV-1<sub>AD8</sub> gp120-expressing plasmid to generate 293 cell lines that stably expressed HIV-1<sub>AD8</sub> gp120 under selection of puromycin. In parallel, we used polyethyleneimine (PEI) to transiently transfect FreeStyle 293 F cells with the identical HIV-1<sub>AD8</sub> gp120-expressing plasmid. Stable 293-AD8gp120 cells grew in media complemented with a feed supplement to a density of >1E7 cells/mL and produced an average of ~150 mg of gp120/liter of the culture, which was about 50-fold higher than the yield of gp120 produced by transient transfection of FreeStyle 293 F cells. SDS-PAGE analysis of HIV-1<sub>AD8</sub> gp120 produced by the two different methods showed similar patterns, but gp120 purified from the stable cell line exhibited higher homogeneity. Binding of anti-gp120 antibodies to gp120 that was produced by the two methods was comparable according to ELISA. Both gp120s could bind equally well to soluble CD4 and compete with infection of viruses pseudotyped with HIV-1<sub>AD8</sub> Envs. Our findings highlight multiple advantages of producing HIV-1<sub>AD8</sub> gp120 by stable expression for downstream applications.IMPORTANCEThere are approximately 40.8 million people living with HIV-1 (PLWH) worldwide, with an estimate of about 1.3 million new HIV-1 infections in 2024, highlighting the urgent need for an effective HIV-1 vaccine and cure strategies. Here, we describe a highly efficient method to produce soluble HIV-1 gp120, which is intensively used in viral assays and for vaccine development. The method may be helpful in research work that needs high amounts of proteins for diverse experiments.

Authors

Institutions

Publication Details

Journal
Journal of Virology
Published
2025-11-07
DOI
https://doi.org/10.1128/jvi.01359-25
Primary Topic
HIV Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Highly efficient production of HIV-1 AD8 gp120 in mammalian cells

Shamim Ahmed, Durgadevi Parthasarathy, Alon Herschhorn, Tanvi Mathur
Journal of Virology
HIV Research and Treatment
article

Highly efficient production of HIV-1 AD8 gp120 in mammalian cells

Shamim Ahmed, Durgadevi Parthasarathy, Alon Herschhorn, Tanvi Mathur
article en

Abstract

Human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins (Envs) interact with the CD4 receptor and CCR5/CXCR4 coreceptor expressed on target cells to mediate viral entry. Infection is initiated when the HIV-1 gp120 subunit of Envs binds to host receptors. gp120 can also be expressed as a soluble protein and is routinely used for different biophysical and immunization studies. Here, we compared the transient and stable expression of monomeric HIV-1<sub>AD8</sub> gp120 in two closely related 293 cell lines grown in suspension. We used an HIV-1<sub>AD8</sub> gp120-expressing plasmid to generate 293 cell lines that stably expressed HIV-1<sub>AD8</sub> gp120 under selection of puromycin. In parallel, we used polyethyleneimine (PEI) to transiently transfect FreeStyle 293 F cells with the identical HIV-1<sub>AD8</sub> gp120-expressing plasmid. Stable 293-AD8gp120 cells grew in media complemented with a feed supplement to a density of >1E7 cells/mL and produced an average of ~150 mg of gp120/liter of the culture, which was about 50-fold higher than the yield of gp120 produced by transient transfection of FreeStyle 293 F cells. SDS-PAGE analysis of HIV-1<sub>AD8</sub> gp120 produced by the two different methods showed similar patterns, but gp120 purified from the stable cell line exhibited higher homogeneity. Binding of anti-gp120 antibodies to gp120 that was produced by the two methods was comparable according to ELISA. Both gp120s could bind equally well to soluble CD4 and compete with infection of viruses pseudotyped with HIV-1<sub>AD8</sub> Envs. Our findings highlight multiple advantages of producing HIV-1<sub>AD8</sub> gp120 by stable expression for downstream applications.IMPORTANCEThere are approximately 40.8 million people living with HIV-1 (PLWH) worldwide, with an estimate of about 1.3 million new HIV-1 infections in 2024, highlighting the urgent need for an effective HIV-1 vaccine and cure strategies. Here, we describe a highly efficient method to produce soluble HIV-1 gp120, which is intensively used in viral assays and for vaccine development. The method may be helpful in research work that needs high amounts of proteins for diverse experiments.

Journal of VirologyVol. 99(11)
University of Minnesota (US), Io Therapeutics (United States) (US)
Openalex Percentile: Top 65%
HIV Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.